Dashboard

Transgene (Euronext: TNG),

part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.

The Company’s lead clinical-stage programs are: TG4010 for non-small cell lung cancer, TG4001 for HPV-positive head and neck cancers, and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, in China and in the U.S.

Stock

Loading…

Corporate Presentation (November 2018)

Corporate Presentation

Press Releases

Receive email alerts

Financial Information


Key figures

In € million
except share and per share data
2017 2016 2015 2014 2013
Revenue 8.1 10.3 9.9 11.1 15.7
R&D Expense -30.4 -26.4 -32.1 -41.7 -50.1
G&A Expense -5.7 -6.2 -5.8 -7.6 -6.8
Net Loss -32.3 -25.2 -46.4 -48.6 -42.9
Net Cash Burn -28.1 -30.6 -34.8 -44.9 -45.0
Cash & Cash Equivalents 41.4 56.2 31.6 65.9 47.9
Loss per Share (Basic and Diluted) -0.52 -0.45 -1.20 -1.26 -1.34
Shares Outstanding 62,075,190 56,431,991 38,545,397 38,527,968 31,874,858


Financial Reports

Years Quarterly Reports Interim Report Registration
Document
First Second Third Fourth
2018        
2017            
2016            
2015              
2014            
2013            
2012            


Regulated Information

Rights issue (October-November 2016)

Chairman’s report on corporate governance and internal controls

Auditors’ Fees

Monthly information on shares outstanding and voting rights (French only)

Stock Information


General

Stock Market Euronext Paris – Eurolist (compartment B)
Reuters / Bloomberg TRNG.PA / TNG.FP
ISIN Code FR0005175080
Total number of shares outstanding 62,275,923
Initial Public Offering (IPO) March 26, 1998
Local Sector Index Next Biotech / CAC Mid 100
Financial Year Ends December 31


Stock Price

Loading…



Shareholder structure

graph shareholder structure

Analysts

Company Analyst E-mail Phone
Bryan Garnier & Co. Ltd Jean-Jacques Le Fur jjlefur@bryangarnier.com +33 (0)1 70 36 57 45
Edison Investment Juan Pedro R. Serrate jpserrate@edisongroup.com +44 (0)20 3077 5700
+44 (0)20 3681 2534
Invest Securities Martial Descoutures mdescoutures@invest-securities.com +33 (0)1 44 88 88 09
Kempen & Co. Suzanne van Voorthuizen suzanne.vanVoorthuizen@kempen.com +31 (0)20 348 8484
Kepler Cheuvreux Thomas Guillot tguillot@keplercheuvreux.com +33 1 70 98 85 27
Life Science Capital LLC Jacques A. Villefranc jacques@lifesciadvisors.com +1 646 597-6997
Oddo BHF Pierre Corby pierre.corby@oddo-bhf.com +33 (0)1 44 51 85 00

Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.


Investor Events & Presentations


Financial Calendar



Investor Events

  • January 8, 2018 - J.P. Morgan Healthcare Conference: January 8 to 10, 2018 – San Francisco, USA
  • January 11, 2018 - Oddo Forum: January 11 & 12, 2018 – Lyon, France
  • March 21, 2018 - Biotech Agora: March 21, 2018 – Paris
  • April 4, 2018 - Portzamparc MidCap Conference: 4 April 2018 – Paris, France
  • April 9, 2018 - H. C. Wainwright Global Life Sciences Conference: April 9, 2018 – Monte Carlo, Monaco
  • April 16, 2018 - Small Cap Event – April 16 & 17, 2018 – Paris
  • April 18, 2018 - Kempen 11th Life Sciences Conference: April 18 & 19, 2018 – Amsterdam, Netherlands
  • June 20, 2018 - Citi: Speed Dating Session @European Healthcare Conference: June 20, 2018 – London, UK
  • June 21, 2018 - Kepler Biotech Days: June 21, 2018 – Paris, France
  • June 27, 2018 - Spring Midcap Event: June 27 & 28, 2018 – Paris, France
  • September 5, 2018 - H. C. Wainwright Annual Global Investment Conference: September 5 & 6, 2018 – New York, USA
  • September 5, 2018 - Séminaire Biotech Portzamparc: September 5, 2018 – Paris, France
  • October 8, 2018 - Large & Midcap Event: October 8 & 9, 2018 – Paris, France
  • November 22, 2018 - Actionaria: November 22 & 23, 2018 – Paris, France
  • November 23, 2018 - Bryan Garnier, Annual Healthcare Conference: November 23, 2018 – Paris, France
  • November 26, 2018 - Eigenkapital Forum: November 26 & 27, 2018 – Frankfurt, Germany
  • December 4, 2018 - Geneva MidCap Event: December 4 & 5, 2018 – Geneva, Switzerland

Corporate Governance

Transgene complies with the corporate governance recommendations of the MiddleNext Code of Governance for Mid and Small Caps (the Code) (Code de gouvernement d’entreprise des valeurs moyennes et petites de MiddleNext). MiddleNext is an independent society representing midcap public issuers; the Code is largely referred to by small, mid and even large cap firms and accepted by regulators as guidance for best governance practices.

 

Board of Directors

The Board of Directors is currently composed of ten members, elected for renewable three-year terms. Six members of the Board are independent directors as defined in the Code. The Board is chaired by the Chairman and Chief Executive Officer. The Board has adopted a charter of internal regulations that governs the conduct of the Board of Directors and its committees. Detailed information can be found in the Registration Document.

The Board of Directors is assisted by two committees:

The Audit Committee is composed of four directors of the Board, three of whom are independent. The Vice President Finance is invited to attend each Committee meeting to present the financial situation of the Company. The Audit Committee’s operations are governed by a charter that is reviewed regularly. The committee regularly reports on its work and provides recommendations to the Board of Directors.

The Compensation Committee is composed of two independent directors and is responsible for recommending to the Board of Directors the salaries, bonuses and share-based compensation to executives and key personnel of the Company.

 

Management Committee

The Management Committee is a non-statutory body that oversees the Company’s daily operations and ensures, in all managerial aspects, that the Company’s strategy is properly executed in accordance with its objectives. The committee is composed of nine members

The Company has established a number of other internal bodies and procedures, for example, for financial controlling, project management and risk management.

Annual General Meeting

Annual General Meeting of May 23, 2018
ORDINARY AND EXTRAORDINARY MEETING

Location
TRANSGENE
400 boulevard Gonthier d’Andernach – Parc d’Innovation
67400 ILLKIRCH-GRAFFENSTADEN – FRANCE

Date and Time
23 May 2018 at 10am

Documents